Allergan delivered good results in the third quarter, in spite of the strong U.S. dollar relative to virtually all major currencies. The U.S.-based company reported product sales of $1,391.1 million for the quarter ended Sept. 30, representing a 6.1 percent increase over the same period a year earlier, or 9.4 ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.